ArticleFrontiers in cardiovascular medicine2025
Short-term changes of right ventricular-pulmonary artery coupling after TAVR and their association with clinical outcomes.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prognostic significance of the trajectories of right ventricular-pulmonary artery (RV-PA) coupling after transcatheter aortic valve replacement (TAVR) remains underexplored. Objectives: This study aimed to (1) characterize the short-term changes of RV-PA coupling (assessed by TAPSE/PASP ratio) from baseline to approximately 3 months after TAVR, and (2) analyze its association with clinical outcomes, including all-cause mortality. Methods: In this retrospective analysis, a total of 210 severe AS patients undergoing TAVR from July 2017 to April 2023 were included based on complete information and were divided into four groups according to the longitudinal changes in RV-PA coupling status. RV-PA coupling was defined as the TAPSE/PASP ratio (normal coupling: >0.55; uncoupling: ≤0.55). Observations included all-cause mortality, heart failure rehospitalization, and NYHA functional class. Results: Among those with normal RV-PA coupling at baseline ( Conclusion: Persistent RV-PA uncoupling after TAVR independently predicts adverse outcomes. Serial assessment of RV-PA coupling enhances risk stratification, supporting tailored post-procedural management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.